The 7investing Podcast

It's been a volatile few months for the stock markets. But long-term investing will endure. The ups and the downs have some investors feeling queasy. Whether it be rising inflation, the Fed considering interest rate hikes, or geopolitical instability, there is no shortage of headlines that might make you believe now is the time to sell everything and head for the hills. But the stock market is also incredibly resilient, and broader-market selloffs can be incredible opportunities to start building long-term positions. When stocks go on sale, it's great to have a watchlist ready. One of our very own 7investing principles is that time is on your side and is the ally of the long-term investor. One of our affiliate partners, Nathan Worden, is similarly interested in empowering others to be long-term investors. He hosts a monthly "Market Game", where contestants pitch ideas to one another with a long-term investing perspective. We've had a lot of fun attending his March Madness inspired presentations before. And we even recently found ourselves competing in one of them! In this episode of our podcast, Nathan chats with 7investing CEO Simon Erickson about his investing style and how he would like to use his Market Game to empower and inspire others. He then runs through four of its most memorable pitches -- including Constellation Brands (NYSE: STZ), Moody's (NYSE: MCO), Vonage (Nasdaq: VG), and Ethereum -- and explains why these might be great long-term investments. Publicly-traded companies and cryptocurrencies mentioned in this podcast include Constellation Brands, Moody's, Vonage, and Ethereum. 7investing's advisors or its guests may have positions in the companies mentioned. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education: https://www.7investing.com Join the 7investing Community Forum: https://discord.gg/6YvazDf9sw Follow us: ► https://www.facebook.com/7investing ► https://twitter.com/7investing ► https://instagram.com/7investing

For decades now, investors have gotten used to companies raising money through the traditional IPO. As an opportunity to access the public markets, they would hire underwriters to purchase their shares at a specific price, who would then release and distribute them to the public markets. Yet critics of the traditional IPO have pointed to the all-too-frequent "IPO Pop" phenomenon. Shares would typically get sold to the underwriters at a price below their true market value. And on the first day of trading, the company's market cap would expand to better fit that actual investor potential. It wouldn't be uncommon to see a company's share price double on its first day of trading. We're living in a more efficient world now, where there are new options available for companies to raise money. Direct Listings and Special Purpose Acquisition Companies (SPACs) are alternatives where companies can raise funds without giving away a massive cut to the underwriters. By using digital marketing, they can further appeal directly to their most loyal fans -- and then convert them into part-owners of the business. This is exactly the future that Toronto-based DealMaker envisions. Its cloud-based platform is allowing for companies to raise money as efficiently and transparently as possible. Imagine doing a campaign where you want to raise $1 million for your business. But rather than using Kickstarter or Indiegogo, you can connect directly with your audience and not have to pay them the platform fees. Additionally, you can continually see who's interested -- and get access to more information that could inform the valuation of your future capital raises as well. An example of this was last year's capital raise by the Green Bay Packers. The NFL football team used DealMaker to self-raise $30 million in 48 hours. The Packers are a publicly-owned team and have been for the past 80 years. This was a much more efficient option for them to raise money. In this exclusive interview with 7investing founder Simon Erickson, DealMaker's co-founders Rebecca Kacaba and Mat Goldstein share the pain-points they saw in the financial services industry that led them to create their company. They describe why "self-hosted funding" is becoming an intriguing opportunity, and why establishing a direct connection with investors is important. The two also offer their thoughts about IPOs, Direct Listings, SPACs, blockchains, and NFTs. Publicly-traded companies and teams mentioned in this podcast include The Green Bay Packers. 7investing's advisors or its guests may have positions in the companies mentioned. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education: https://www.7investing.com Join the 7investing Community Forum: https://discord.gg/6YvazDf9sw Follow us: ► https://www.facebook.com/7investing ► https://twitter.com/7investing ► https://instagram.com/7investing

The disruptive potential of gene editing could have huge implications for health care. Suddenly, several chronic diseases -- which may have required patients to be treated for decades -- have a potential to be fundamentally cured at the genomic level. This is unlocking publicly-tradable investment opportunities. Companies are utilizing the power of CRISPR gene editing, base editing, and prime editing to directly modify patient DNA. Larger pharmaceutical companies are partnering with these smaller drug developers and are building commercial programs that could be worth billions of dollars. Genetic sequencing companies are reducing costs and unlocking broader market adoption, which is rewarding them with greater volumes and higher profits. These opportunities are what has led Kelly ETFs to launch its newest investment product, the CRISPR & Gene Editing Technology ETF (Nasdaq: XDNA). In this exclusive conversation with 7investing CEO Simon Erickson, Kelly ETFs founder Kevin Kelly describes why he brought the ETF to market and how it is less-correlated with other health care funds that are available. He describes his allocation approach and why he isn't afraid to take large stakes in smaller companies. The two also dig into several of the ETF's largest positions, including Beam Therapeutics (Nasdaq: BEAM), Intellia Therapeutics (Nasdaq: NTLA), and Illumina (Nasdaq: ILMN). Publicly-traded companies mentioned in this interview include Abbott Laboratories, Beam Therapeutics, CRISPR Therapeutics, Editas Medicine, Illumina, Intellia Therapeutics, Regeneron, and Thermo Fisher. 7investing's advisors or its guests may have positions in the companies mentioned. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Join the 7investing Community Forum: https://discord.gg/6YvazDf9sw Follow us: ► https://www.facebook.com/7investing ► https://twitter.com/7investing ► https://instagram.com/7investing

The financial industry is in a familiar place: Legacy banks are being challenged by technologically savvy, disruptive upstarts. Is the banking world about to be turned upside down? Veteran banking analyst and writer John Maxfield doesn't think so. Maxfield is the executive director of the Wilmers Integrity Prize, named after Robert Wilmers, the longtime CEO of MMT Bank. He was formerly the editor-in-chief for Bank Director magazine. Maxfield joined 7investing lead advisor Matthew Cochrane to take a tour of the financial industry, starting with a look at whether neobanks, such as Chime, are a product of VC-backed cheap capital or a legitimate threat to legacy banks. While acknowledging technology is playing a disruptive role in the banking industry overall, Maxfield believes big banks especially have the firepower to keep pace in the rapidly changing industry while wondering if the smaller upstarts can even achieve profitability. Next, Maxfield and Cochrane explore the recent explosion in M&A activity in the banking space. In 2019, SunTrust came together with BB&T in a merger of equals, creating Truist Financial Corp (NYSE:TFC), the 6th largest bank in the U.S. by assets. This was followed last June by PNC Financial Services Group (NYSE:PNC) completing its $11.5B acquisition of BBVA USA, making it one of the largest U.S. commercial banks. Banking consolidation is a phenomenon that Maxfield traces back to the early 1980s when Congress allowed banks to acquire financial institutions in other states. While Maxfield believes this trend will stay intact, he questions whether the majority of such deals create value for shareholders. Of course, no discussion about the banking space is complete without a tour of the big four banks dominating the domestic landscape: Bank of America (NYSE:BAC), Citigroup (NYSE:C), JPMorgan Chase (NYSE:JPM), and Wells Fargo (NYSE:WFC). Finally, Maxfield explains why Triumph Bancorp (NASDAQ:TBK) is a hidden gem, an under-the-radar community bank based in Dallas, TX, attempting an ambitious project in a big industry! Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Join the 7investing Community Forum: https://discord.gg/6YvazDf9sw Follow us: ► https://www.facebook.com/7investing ► https://twitter.com/7investing ► https://instagram.com/7investing

Do you find your emotions dictating your investment decisions, or use margin trading or derivatives to try to magnify your investment returns? In difficult market conditions with growth stocks facing significant drawdowns almost daily, are you tempted to chase your losers, hoping to get even? If so, you may be falling prey to one or more of the ‘seven deadly sins during a market selloff’! In this episode of the 7investing podcast, Lead Advisors Anirban Mahanti and Luke Hallard discuss seven products and habits that can cause tremendous damage to an investor’s long-term returns. Not only will these behaviours likely cause you to lose sleep at night, but they can also have a big impact on your portfolio. Publicly-traded companies mentioned in this podcast include GameStop, Apple, Netflix and Tesla. 7investing Lead Advisors Anirban Mahanti and Luke Hallard may own shares in the companies mentioned in the podcast. Timestamps 00:00 - Introduction 01:35 - Using Margin 03:50 - Shorting Stocks 06:57 - Short-Term Options 11:48 - Emotional Trading/FOMO 13:31 - Growth Investors Chasing Defensive Stocks 16:28 - Selling Positions to Start or Add to Positions 18:25 - Chasing Your Losers Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Join the 7investing Community Forum: https://discord.gg/6YvazDf9sw Follow us: ► https://www.facebook.com/7investing ► https://twitter.com/7investing ► https://instagram.com/7investing

We’re only four weeks in, and 2022 is already proving to be an eventful year. Between the S&P 500 and the Nasdaq’s recent corrections, concerns about a war between Russia and Ukraine, and the Fed’s promises of an upcoming rate hike, the new year has brought more than a few interesting financial media headlines. While the upcoming Year of the Tiger is still a young cub, we figured now was the time to make a few reckless predictions. Our 7investing advisors gathered together to have some fun, and we came up with five “hey it could happen” prognostications that could have significant impacts for investors in 2022. Steve Symington believes a small & mid cap rally is inevitable, while Maxx Chatsko believes CRISPR and gene editing are prone to come back down to earth. Anirban Mahanti thinks Peloton (Nasdaq: PTON) might soon be acquired, and Dana Abramovitz believes Facebook/Meta Platforms (Nasdaq: FB) is destined to enter health care. And 7investing founder and CEO Simon Erickson believes this is the year that the US will finally put a ban on Payments for Order Flow. While we’re not guaranteeing a 1.000 success rate (these are “reckless”, after all!), we do enjoy thinking out loud about what innovation in the markets could mean for stock investors. If you’d like to join the fun and discuss any of our predictions in greater detail, please bring your thoughts to our newly-launched 7investing Community Forum. Publicly-traded companies mentioned in this interview include Crispr Therapeutics, Meta Platforms, Peloton, and Robinhood. 7investing’s advisors or its guests may have positions in the companies mentioned. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Join the 7investing Community Forum: https://discord.gg/6YvazDf9sw Follow us: ► https://www.facebook.com/7investing ► https://twitter.com/7investing ► https://instagram.com/7investing

Given the rise of exciting new therapeutic modalities ranging from mRNA to gene editing, investors would be forgiven for overlooking opportunities in medical devices. They might be worth a closer look though. In this episode of the 7investing podcast, the team's health-care trio provide a high-level overview of the regulatory environment for medical devices, describe why and how genetic tests are regulated as medical devices, and provide three examples of companies in the space and how they fit within the regulatory landscape. Medical devices are regulated by the U.S. Food and Drug Administration (FDA) within three categories: Class I devices are the simplest and least likely to pose safety risks. Examples include bedpans or medical gauze. These require regulatory clearance. Class II devices are more complicated and require more data within their regulatory submissions to ensure the safety and effectiveness of the device. Examples include X-ray machines or knee braces. These require regulatory clearance. Class III devices are the most complicated and pose the greatest potential risk to patients, such as life-supporting, life-sustaining, or implantable devices. Examples include liquid biopsies, pacemakers, or implantable contact lenses. These require regulatory approval. Although Class I and Class II medical devices can be submitted through the 510(k) process and only need to show equivalence to a predicate ("existing") device, Class III medical devices must be submitted through the more rigorous premarket approval (PMA) process that often requires a clinical trial. Unlike a drug candidate that requires at least three separate clinical trials (phase 1, phase 2, and phase 3), a Class III medical device often only requires a single clinical trial. It seems odd, but genetic tests and liquid biopsies are also regulated as medical devices. These product candidates are categorized into one of the classes above, which typically impacts how and where they can be used. The three designations of genetic tests include: Research use only (RUO) products cannot be used as diagnostics and don't require a regulatory submission. RUOs can form the basis of a more advanced diagnostic product from the originator or its customers. These serve an important role, but generally have the smallest market opportunity. Laboratory developed tests (LDT) must be designed, manufactured, and processed by a single CLIA-certified laboratory. These tend to be Class II medical devices and require a 510(k) filing. LDTs are often used with centralized business models, where patient samples are shipped to a centralized facility. Examples include genetic screening tests. These have the largest volume potential, but low to moderate pricing and insurance coverage. These have moderate to large market opportunities. In vitro diagnostics (IVD) are more robust tests and can be shipped to the point of care, which means placed in the hands of doctors, oncologists, and medical facilities. Because these are not self-contained within CLIA-certified labs, they're often classified as Class III medical devices and require a PMA filing and clinical trial. IVDs are often used with distributed business models, where patient samples are processed at the point of care. Examples include liquid biopsies. These have both large volume and high price potential, which results in the largest market opportunities by monetary value. Finally, the podcast concludes with three different examples of medical device companies: 7investing Lead Advisor Dana Abramovitz discusses Inviate (NYSE: NVTA). 7investing Lead Advisor Maxx Chatsko discusses Nano-X Imaging (NASDAQ: NNOX). 7investing Lead Advisor Simon Erickson discusses STAAR Surgical (NASDAQ: STAA)

We are very excited to welcome Luke Hallard as our newest 7investing lead advisor! Luke has a degree in Computer Science from the University of Wales, Aberystwyth. His first role was as a software engineer in the team developing the air-traffic control system that still manages all UK and transatlantic airspace. He transitioned from technology to finance in 1996, joining HSBC James Capel Investment Bank, and in 2021 retired from a 25-year career as a Programme Director leading organizational change. Luke’s knowledge of conduct, financial crime risk, data privacy, sanctions screening, anti-money laundering, and payments transparency is happily fading into a hazy memory of bureaucracy and complexity. Luke primarily invests in technology and innovation, with a current bias towards health-tech and companies enabling the 'work from anywhere' economy. By his own admission, he's not a deep domain expert in any area, and instead invests across many sectors, feeling that this offers greater portfolio agility if market forces don't play out in the way he anticipates. Luke primarily invests in US equities, but he also has a handful of angel investments, with two successful exits to date. Although Luke’s portfolio spans many industries, a key factor his personal investments have in common is that they all seek to make the world a better, less complex place. Luke invests with his head, but his heart occasionally exercises the power of veto. Luke and Simon first met when Simon guested on the Telescope Investing podcast, hosted by Luke and his co-founder Albert. Simon immediately recognized the close affinity between 7investing and the long-term growth investing strategy that Luke has successfully employed through the last eighteen years, delivering a market-beating compound growth rate in his personal portfolio of over 26% annually. Luke holds trustee and grant panel roles with multiple UK charities in the social welfare sector. He’s married to Katrina, and they live in London with their Siberian cat, Sushi. Luke has a passion for health and physical fitness. He’s completed the London Marathon, and is currently training for a 4x4x48 challenge, running four miles every four hours for 48 hours. He dedicates his winters to skiing and snowboarding, and in a final bid to successfully land a back-flip on a board he recently attended trampoline classes. Luke is a motorcycling enthusiast and regularly tours Europe by bike, although his favourite stretches of roads are in Japan. He’s embarrassingly slow on the racetrack despite living fifteen minutes from an internationally renowned motor racing circuit, and spent his younger years volunteering as an observer with the Institute of Advanced Motorcyclists. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us: ► https://www.facebook.com/7investing ► https://twitter.com/7investing ► https://instagram.com/7investing

In 2021, many growth investors suffered severe losses even while the S&P 500 index advanced 27%. A recent Bloomberg article pointed out that almost 40% of the stocks in the Nasdaq Composite Index were down 50% or more from their all-time highs. It continued, "At no other point since the bursting of the dot-com bubble have so many companies fallen like this while the index itself was so close to a peak." Are tech stocks down big because the Federal Reserve expects to raise interest rates several times this year? Did their valuations get too stretched in their post-COVID runup? Tobias Carlisle joined 7investing Lead Advisor Matthew Cochrane this week to help us walk through these challenging questions. Carlisle, the founder and managing director of Acquirers Funds, believes it is important to weigh the company's quality with the valuation investors must pay to buy shares. In an exclusive interview with 7investing, Tobias describes his investment philosophy as "quality at an unreasonable price."  He states that he looks for three primary qualities before investing in a company: 1) a discount to a conservative valuation; 2) a strong, liquid balance sheet; and 3) a robust business capable of generating free cash flows. 7investing Lead Advisor Matthew Cochrane and Tobias Carlisle walk through the definitions of value and growth stocks. Before the conclusion of the interview, they discuss a stock they both like, Lockheed Martin (NYSE:LMT), and some of the qualitative advantages it enjoys as a prime defense contractor. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us: ► https://www.facebook.com/7investing ► https://twitter.com/7investing ► https://instagram.com/7investing

There aren’t many single events that bring together a Who’s Who list of the leading private and public companies in biotech and synthetic biology. The JP Morgan Healthcare Conference is one of the rare exceptions. The annual event, held every January, is one of the biggest stages for companies to reveal innovative new products in development, announce acquisitions, and form landscape-shifting collaborations. Investors were left wanting more after the 2021 meeting, which was relatively subdued due to the coronavirus pandemic. The first few days of the 2022 event seemed to live up to historical expectations, with a handful of companies making splashy announcements so far. In this episode of the podcast, 7investing Lead Advisors Simon Erickson and Maxx Chatsko sit down to provide quick takeaways on some of the biggest reveals from the beginning of the 2022 JP Morgan Healthcare Conference. These include: The unveiling of a long-read DNA sequencing technology from Illumina (NASDAQ: ILMN) and an enzymatic DNA synthesis technology from Twist Bioscience (NASDAQ: TWST). Molecular testing leader Exact Sciences (NASDAQ: EXAS) used the stage to reveal that it comfortably beat full-year 2021 guidance and jump into hereditary cancer testing. Meanwhile, Beam Therapeutics (NASDAQ: BEAM) announced a research collaboration with Pfizer (NYSE: PFE) that had an unusual structure. Simon and Maxx also share their thoughts on the slow pace of merger and acquisitions (M&A) in drug development in the last two years — and why record cash balances and a constant need for innovation at the largest companies suggest that could change in 2022. Publicly-traded companies mentioned or alluded to in this podcast include Beam Therapeutics, CRISPR Therapeutics, Eli Lilly, Exact Sciences, Illumina, Intellia Therapeutics, Novo Nordisk, Pacific Biosciences, and Twist Bioscience. 7investing’s advisors may own positions in the companies that are mentioned. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us: ► https://www.facebook.com/7investing ► https://twitter.com/7investing ► https://instagram.com/7investing